Your browser doesn't support javascript.
loading
Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - First real-world data.
Lucidarme, Jay; Bai, Xilian; Lekshmi, Aiswarya; Clark, Stephen A; Willerton, Laura; Ribeiro, Sonia; Campbell, Helen; Serino, Laura; De Paola, Rosita; Holland, Ann; Louth, Jennifer; Ramsay, Mary E; Ladhani, Shamez N; Borrow, Ray.
Affiliation
  • Lucidarme J; Meningococcal Reference Unit, Public Health England, Floor 2 Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom. Electronic address: jay.lucidarme@phe.gov.uk.
  • Bai X; Meningococcal Reference Unit, Public Health England, Floor 2 Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom.
  • Lekshmi A; Meningococcal Reference Unit, Public Health England, Floor 2 Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom.
  • Clark SA; Meningococcal Reference Unit, Public Health England, Floor 2 Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom.
  • Willerton L; Meningococcal Reference Unit, Public Health England, Floor 2 Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom.
  • Ribeiro S; Immunisation and Countermeasures Division, Public Health England, London, NW9 5EQ, United Kingdom.
  • Campbell H; Immunisation and Countermeasures Division, Public Health England, London, NW9 5EQ, United Kingdom.
  • Serino L; GlaxoSmithKline Vaccines, via Fiorentina 1, 53100, Siena, Italy.
  • De Paola R; GlaxoSmithKline Vaccines, via Fiorentina 1, 53100, Siena, Italy.
  • Holland A; Vaccine Evaluation Unit, Public Health England, Floor 2 Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom.
  • Louth J; Vaccine Evaluation Unit, Public Health England, Floor 2 Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom.
  • Ramsay ME; Immunisation and Countermeasures Division, Public Health England, London, NW9 5EQ, United Kingdom.
  • Ladhani SN; Immunisation and Countermeasures Division, Public Health England, London, NW9 5EQ, United Kingdom; Paediatric Infectious Diseases Research Group, St. George's University of London, Cranmer Terrace, London SW17 0RE, United Kingdom.
  • Borrow R; Meningococcal Reference Unit, Public Health England, Floor 2 Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WL, United Kingdom; Vaccine Evaluation Unit, Public Health England, Floor 2 Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WL, United Ki
J Infect ; 84(2): 136-144, 2022 02.
Article in En | MEDLINE | ID: mdl-34838814
OBJECTIVES: In 2015 the UK became the first country to implement the meningococcal B (MenB) vaccine, 4CMenB, into the national infant program. 4CMenB is expected to cover meningococci expressing sufficient levels of cross-reactive proteins. This study presents clonal complex, 4CMenB antigen genotyping, and 4CMenB coverage data for all English invasive MenB isolates from 2014/15 (1 year pre-vaccine) through 2017/18 and compares data from vaccinated and unvaccinated ≤3 year olds. METHODS: Vaccine coverage of all invasive MenB isolates from 2014/15 to 2017/18 (n = 784) was analysed using the Meningococcal Antigen Typing System. Genotyping utilised the Meningococcus Genome Library. RESULTS: Among ≤3 year olds, proportionally fewer cases in vaccinees (1, 2 or 3 doses) were associated with well-covered strains e.g. cc41/44 (20.5% versus 36.4%; P<0.01) and antigens e.g. PorA P1.4 (7.2% versus 17.3%; P = 0.02) or fHbp variant 1 peptides (44.6% vs 69.1%; P<0.01). Conversely, proportionally more cases in vaccinees were associated with poorly-covered strains e.g. cc213 (22.9% versus 9.6%; P<0.01) and antigens e.g. variant 2 or 3 fHbp peptides (54.2% versus 30.9%; P<0.01). CONCLUSIONS: 4CMenB reduces disease due to strains with cross-reactive antigen variants. No increase in absolute numbers of cases due to poorly covered strains was observed in the study period.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Meningococcal Vaccines / Neisseria meningitidis, Serogroup B / Meningococcal Infections Limits: Child, preschool / Humans / Infant Language: En Journal: J Infect Year: 2022 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Meningococcal Vaccines / Neisseria meningitidis, Serogroup B / Meningococcal Infections Limits: Child, preschool / Humans / Infant Language: En Journal: J Infect Year: 2022 Document type: Article Country of publication: United kingdom